Salut Brunet

Salut Brunet

Auto-generated profile, based on publicly available information

Salut Brunet

Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2006 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
IEIñigo Espinosa
Iñigo Espinosa
JBJavier Briones
Javier Briones
RBRamon Bordes
Ramon Bordes
SBSalut Brunet
Salut Brunet
RODRIGO MARTINORODRIGO MARTINO
RODRIGO MARTINO
JSJorge Sierra
Jorge Sierra

1 September 1999 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
AGA Grañena
A Grañena
XCX Castellsagué
X Castellsagué
IBI Badell
I Badell
CFC Ferra
C Ferra
JOJj Ortega
Jj Ortega
JGJ García
J García

2 February 2018 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
MTMontserrat Torrebadell
Montserrat Torrebadell
MDMarina Díaz-Beyá
Marina Díaz-Beyá
SKSusana G. Kalko
Susana G. Kalko
MPMarta Pratcorona
Marta Pratcorona
JNJosep Nomdedeu
Josep Nomdedeu
JEJordi Esteve
Jordi Esteve
In intermediate-risk cytogenetic acute myeloid leukemia (IRC-AML) patients, novel biomarkers to guide post-remission therapy are needed. We analyzed with high-density arrays 40 IRC-AML patients who received a non-allogeneic hematopoietic stem-cell transplantation-based post-remission therapy, and identified a signature that correlated with early relapse. Subsequently, we analyzed selected 187 genes in 49 additional IRC-AML patients by RT-PCR. BAALC, MN1, SPARC and HOPX overexpression correlated to refractoriness. BAALC or ALDH2 overexpression correlated to shorter overall survival (OS) (5-year OS: 33 ± 8.6% vs. 73.7 ± 10.1%, p = .006; 32 ± 9.3% vs. 66.4 ± 9.7%, p = .016), whereas GPR44 or TP53INP1 overexpression correlated to longer survival (5-year OS: 66.7 ± 10.3% vs. 35.4 ± 9.1%, p = .04; 58.3 ± 8.2% vs. 23.1 ± 11.7%, p = .029). A risk-score combining these four genes expression distinguished low-risk and high-risk patients (5-year OS: 79 ± 9% vs. 30 ± 8%, respectively; p = .001) in our cohort and in an independent set of patients from a public repository. Our 4-gene signature may add prognostic information and guide post-remission treatment in IRC-AML patients.

1 January 2015 in Leukemia Research
Verified
Journal Article
Open access
JFJose Falantes
Jose Falantes
RDRegina García Delgado
Regina García Delgado
CCCristina Calderón-Cabrera
Cristina Calderón-Cabrera
FMFrancisco J. Márquez-Malaver
Francisco J. Márquez-Malaver
DFDavid Valcárcel Ferreiras
David Valcárcel Ferreiras
Guillermo F SanzGuillermo F Sanz
Guillermo F Sanz
Scoring systems for lower-risk myelodysplastic syndrome (LR-MDS) recognize patients with a poorer than expected outcome. This study retrospectively analyzes the role of azacitidine in LR-MDS with adverse risk score and compared to an historical cohort treated with best supportive care or erythropoiesis-stimulating agents. Overall response to AZA was 40%. One and 2-year probabilities of survival were 62% and 45% for AZA vs. 25% and 11% (P=10(-4)). In a multivariable time-dependent analysis, response to AZA (CR/PR/HI) was associated with an improved survival (HR=0.234, 95% CI, 0.063-0.0863; P=0.029). Thrombocytopenia (<50 × 10(9)L(-1)) is confirmed as an adverse parameter in LR-MDS (HR=1.649, 95% CI, 1.012-2.687; P=0.045).

15 October 2018 in Leukemia & Lymphoma
Verified
Journal Article
Open access
JLJorge Labrador
Jorge Labrador
ELElisa Luño
Elisa Luño
EVEdo Vellenga
Edo Vellenga
SBSalut Brunet
Salut Brunet
JGJosé González-Campos
José González-Campos
PMPau Montesinos
Pau Montesinos
Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of ≥2 ACA, and a very CK (CK+) as ≥3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with <2 ACA (p=.09). Among patients with CK+, the 5-year CIR was 27% vs 12% (p=.003), retaining the statistical significance in multivariate analysis. This study shows an increased risk of relapse among APL patients with CK + treated with ATRA plus chemotherapy front-line regimens.

1 November 1997 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
CMC Martínez
C Martínez
ASAnna Sureda
Anna Sureda
RODRIGO MARTINORODRIGO MARTINO
RODRIGO MARTINO
JCJa Cancelas
Ja Cancelas
PMP Madoz
P Madoz
SBS Brunet
S Brunet